Best Gene Editing CDMOs in United States

← All Gene Editing CDMOs Best Clean FDA History Commercial Scale

Region: USA Europe Asia

CDMOs tracked

Fully scored

With FDA records

FDA inspections

EMA/MHRA GMP certs

For US-manufactured gene editing programs, Charles River Laboratories, RoslinCT, and Bayer (Cell Therapy Mfg) lead CDMO Signal's ranking of gene editing CDMOs with confirmed US facilities. Filtered from the global directory of 10 scored gene editing CDMOs to 10 with US manufacturing presence. US-based manufacturing carries specific advantages for sponsors filing under FDA jurisdiction: FDA inspection records — which form the core of the Signal Score's Quality Compliance pillar — apply directly, and QP release complexity common to EU-manufactured material does not apply. Rankings update as new inspection and certificate data enters the platform. Full methodology at cdmosignal.com/methodology.

Gene editing CDMOs support CRISPR, base, and prime editing programs — spanning guide RNA and nuclease (mRNA or protein) supply, delivery (LNP, AAV, or electroporation), and, for ex vivo programs, edited-cell manufacturing.

Because a gene-editing program touches several modalities at once, CDMO selection often hinges on which steps a partner covers in-house versus coordinates. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 11 NAI (no action), 6 VAI (voluntary action), 1 OAI (official action). Leading inspection & GMP sites: Germany (16), United States (15), France (4), Ireland (3), UNITED KINGDOM (3).

Last updated 2026-07-11. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

#	CDMO	Signal Score	Quality	FDA · GMP	Capacity	Programs
1	CR Charles River Laboratories Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD	91.7	98.7	8 insp · 11 GMP	Limited	0 programs
2	RC RoslinCT Edinburgh, UK · Hopkinton, MA	80.2	98.8	1 insp · 1 GMP	Available	0 programs
3	BY Bayer (Cell Therapy Mfg) Berkeley, CA	79.2	86.9	8 insp · 17 GMP	—	125 programs
4	CS Cedars-Sinai Biomanufacturing Los Angeles, CA	78.9	100.0	1 insp · 0 GMP	—	34 programs
5	GP Green Phoenix Labs San Diego, CA	78.1	100.0	0 insp · 1 GMP	—	0 programs
6	GenScript Piscataway, NJ	65.5	—	—	—	0 programs
7	CT CTMC Houston, TX	63.0	—	—	—	0 programs
8	AP Applied StemCell Milpitas, CA	60.5	—	—	—	0 programs
9	C3 C3i Center Houston, TX	59.0	—	—	—	0 programs
10	PO Poseida Therapeutics (CDMO) San Diego, CA	58.7	—	—	—	6 programs
—	Rose BioSolutions Wilmington, MA	Profiled	—	—	—	0 programs
—	Full Circles Therapeutics San Francisco, CA	Profiled	—	—	—	0 programs
—	Landmark Bio Watertown, MA	Profiled	—	—	—	0 programs

How we score CDMOs →

What to evaluate in a Gene Editing CDMO

Editing components

Confirm supply of guide RNA and nuclease (Cas mRNA or protein) — in-house or sourced — and the quality controls on each.

Delivery modality

In vivo editing needs LNP or AAV delivery; ex vivo needs electroporation and cell handling. Match the CDMO's delivery experience to your approach.

Ex vivo cell manufacturing

For edited cell therapies, evaluate closed-system cell processing and chain-of-identity, as with other cell therapies.

Regulatory track record

Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

FDA jurisdiction — how the ranking scores US-based CDMOs

The Signal Score's Quality Compliance pillar (35% of the composite) is dominated by FDA inspection data for US-based CDMOs: Establishment Inspection Report classifications (NAI, VAI, OAI), Form 483 observation counts, and Warning Letter history. For a CDMO whose primary facility footprint is US, this pillar carries direct weight — an inspection on the site slated for a sponsor's program applies without translation. For CDMOs with mixed US + international facility footprint, the ranking reflects the composite regulatory posture; sponsors evaluating for a specific program should verify inspection history on the exact US site under consideration via that CDMO's profile page.

Which US CDMOs also cover EU and UK regulatory geographies?

Many top-tier US-based CDMOs maintain EU (EMA) and UK (MHRA) GMP certification for facilities used to supply EU and UK trials or commercial markets. The Signal Score's Quality Compliance pillar includes EMA + MHRA certificate density as a component — a US-headquartered CDMO with dense EU/UK certificates typically ranks higher on this pillar than a US-only competitor. Sponsors running dual-jurisdiction programs should cross-check the individual CDMO profile pages for specific certificate coverage; the Europe region ranking surfaces CDMOs that also appear in the European jurisdiction ranking, indicating multi-region regulatory posture.

How CDMO Signal identifies US manufacturing presence

Region attribution is derived from each CDMO's declared facility locations in our directory. A CDMO's facility list is validated against corporate filings, press releases, and — where public — the FDA facility registration (FEI number lookups). Region matching is done at the country level: a US state name or two-letter abbreviation in the facility list places the CDMO in the US region. CDMOs with US + international sites appear in every applicable region ranking, which reflects operational reality — such a CDMO is a legitimate candidate for programs in any of those jurisdictions.

Gene Editing CDMOs — Frequently Asked Questions

Who are the top Gene Editing CDMOs?

By CDMO Signal's independent Signal Score, the top-ranked Gene Editing CDMOs include Charles River Laboratories, RoslinCT, Bayer (Cell Therapy Mfg). See the full ranked table above — scored on FDA, clinical, financial, and capacity data.

How many Gene Editing CDMOs have FDA inspection records?

CDMO Signal tracks 4 Gene Editing CDMOs with FDA inspection records and 30 EMA/MHRA GMP certificates across the group.

What should I look for in a gene editing CDMO?

Map the steps you need — guide RNA and nuclease supply, delivery (LNP/AAV/electroporation), and edited-cell manufacturing — and confirm which the CDMO covers in-house versus coordinates, plus a clean FDA and EMA/MHRA record.

Why do gene editing programs use multiple CDMOs?

A single program may need guide RNA, a nuclease, a delivery vehicle, and cell manufacturing — distinct capabilities. Some CDMOs cover several in-house; many programs combine specialists.

Related modalities

Cell Therapy CDMOs AAV / Gene Therapy CDMOs mRNA / LNP CDMOs

Other Modalities

AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Exosome Recombinant Proteins ADC